Effects of chrysotherapy on cell mediated immune response.
Auranofin (AF) differs significantly from gold sodium thiomalate (GSTM) in formulation, i.e., aurous gold is stabilized by dual sulfur and phosphorus ligands, hydrophobic rather than hydrophilic characteristics, and lack of ionic charge. These attributes facilitate: oral absorption of AF, plasma membrane penetration, increase in intracellular lymphocyte gold concentration; and perhaps thereby influence lymphocyte function. AF treated subjects recorded prompt and sharp declines in mitogen-induced lymphoproliferative response (LMR) greater than 80%; suppressed response to skin testing with dinitrochlorobenezene (DNCB) in 11 of 14 subjects; and blebbing of lymphocyte membranes by scanning electron microscopy. In contrast, lymphocytes from a matched group of GSTM treated subjects recorded later onset and less suppression of LMR; normal response to DNCB skin testing; and did not manifest membrane blebbing. Accordingly, the therapeutic action of AF on immune response was observed in the 16 subjects receiving 6 mg/d of an average of 45 weeks to effect primarily cell mediated rather than humoral immune response when compared with a matched group of GSTM treated patients.
D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000473:pathology; D001310:Auranofin; D006051:Aurothioglucose / Q000031:analogs & derivatives / Q000627:therapeutic use; D006046:Gold / Q000032:analysis / Q000097:blood / Q000494:pharmacology*; D006052:Gold Sodium Thiomalate / Q000494:pharmacology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects*; D008214:Lymphocytes / Q000032:analysis / Q000473:pathology; D008934:Mitogens / Q000276:immunology; D012882:Skin Tests
D008934:Mitogens; D006052:Gold Sodium Thiomalate; D006051:Aurothioglucose; D001310:Auranofin; D006046:Gold